Just about to shut down & a new vblog post from Dr. Myers comes in. Very timely, considering my mention of estradiol [E2] patches as an alternative to Zometa for ADT-related osteoporosis.
I was a bit cautious in the Zometa post, because I'm not aware of a study that showed that an estradiol patch could eliminate the risk of osteoporosis while on ADT. Some think that male bone health requires testosterone too. Myers quashes that idea in the video. He mentions patients that arrive with osteopenia & gain bone mineral density while on ADT - because of the E2 patch.
I have an issue with how he deals with E2 & clotting risk. The aim of the E2 patch when used with Lupron, say, is to restore E2 to a normal level for bone health. Normal male E2 levels do not cause clots.
The patch he uses is the Vivelle-Dot 0.025 mg estradiol patch. He does not mention a target, but E2 = 20 pg/mL is ideal IMO. E2 should not go below 12 or above 30 pg/mL. Life Extension has long touted 20-30 pg/mL as optimal, but aging men not on ADT often have sub-optimal testosterone [T], & my personal view is that the E2:T ratio matters. In any case, there seems to be no advantage in having E2 above 20 pg/mL.
Dr Myers deals with E2-clotting concerns by denying that estrogen causes abnormal coagulation in men. E2 is associated with clots in women, but men are not women, he says(!) OK, but before Lupon (1985), the synthetic estrogen Diethylstilbestrol [DES] had been used since 1941. High doses (5 mg or higher) were associated with thromboembolic events. Today, there is interest in DES at 1 mg or thereabouts, which is considered to be less risky.
There is a 1996 study [1]:
"The association of hyperestrogenemia with coronary thrombosis in men."
"Estradiol was the only variable measured that showed a significant relationship to {myocardial infarction} ... These findings suggest that hyperestrogenemia may be related to the thrombosis of {myocardial infarction}."
Anyway, here is Dr Myers:
askdrmyers.wordpress.com (May 27, 2016 post)
-Patrick